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BACKGROUND: Clinical testing of new therapeutic interventions requires comprehensive, high-quality preclinical
data. Concerns regarding quality of preclinical data have been raised in recent reports. This report examines the
data on the interaction of 10 drugs with radiation and provides recommendations for improving the quality,
reproducibility, and utility of future studies. The drugs were AZD6244, bortezomib, 17-DMAG, erlotinib, gefitinib,
lapatinib, oxaliplatin/Lipoxal, sunitinib (Pfizer, Corporate headquarters, New York, NY), thalidomide, and vorinostat.
METHODS: In vitro and in vivo data were tabulated from 125 published papers, including methods, radiation and
drug doses, schedules of administration, assays, measures of interaction, presentation and interpretation of data,
dosimetry, and conclusions. RESULTS: In many instances, the studies contained inadequate or unclear information
that would hamper efforts to replicate or intercompare the studies, and that weakened the evidence for designing
and conducting clinical trials. The published reports on these drugs showed mixed results on enhancement of
radiation response, except for sunitinib, which was ineffective. CONCLUSIONS: There is a need for improved
experimental design, execution, and reporting of preclinical testing of agents that are candidates for clinical use in
combination with radiation. A checklist is provided for authors and reviewers to ensure that preclinical studies of
drug-radiation combinations meet standards of design, execution, and interpretation, and report necessary
information to ensure high quality and reproducibility of studies. Improved design, execution, common measures
of enhancement, and consistent interpretation of preclinical studies of drug-radiation interactions will provide
rational guidance for prioritizing drugs for clinical radiotherapy trials and for the design of such trials.
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State-of-the-art cancer treatment includes chemo-/radiotherapy for
most tumor sites, but the integration of targeted agents into radio- or
chemoradiotherapy will be key to further optimizing treatment
responses. The decision to embark on clinical trials of radiotherapy
with new anticancer agents should be based on solid preclinical
evidence. Because of broadly based concerns about the reproducibility
and translation of preclinical studies to the clinic [1–3], we conducted
a critical survey of 125 published preclinical studies testing the
interaction with radiation of 10 agents of interest to the Cancer
Therapy Evaluation Program of the National Cancer Institute
(Figure 1). The rationale was that these agents had demonstrable
Figure 1. Top: drugs surveyed and numbers of papers reviewed.
Bottom: distribution of papers reporting in vitro or in vivo studies or
both. Synonyms and properties of drugs are listed in Supplemen-
tary Table 1. Papers with both oxaliplatin and LipoxalTM were not
counted twice for totals.
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enhance radiation response. Supplementary Table 1 shows drug
synonyms and properties. The survey covered research reports
presenting original data that measured tumor cell killing by radiation
plus drug in vitro or tumor response in vivo published before
November 13, 2014. Experiments on normal cells and tissues were
not evaluated but are important in assessing clinical potential because
a therapeutic gain can be achieved only when the effect on the tumor
is greater than on the surrounding normal tissues. Mechanistic studies
are also important but were not evaluated in this survey. Both would
be worthy of separate examination.
Materials and Methods
Searches and Drugs
Searches were conducted using PubMed and the National Library
of Medicine, using as search terms the drug name and “radiation,”
and limited to English-language papers available through the National
Institute of Health Library’s Online Journals. A reference list of
papers surveyed is included in Supplementary Table 2.
Analysis Methodology
We examined only data involving single drugs and radiation; these
were sometimes control groups in studies of multidrug combinationswith radiation. For all studies, we recorded drug, drug concentration
or dose, cell line(s) and origin (type of tumor, human or animal), assay
and end point, treatment schedule, measure of interaction, radiation
parameters (source, energy, dose[s], dose rate, setup, dosimetry), and
authors' conclusions and comments. For in vitro studies, we recorded
schedule of plating, number of repeats, replicate plates, and plate or
flask size. For in vivo studies, we recorded tumor transplant site and
size at start of treatment and number of animals/group. To facilitate
intercomparison of treatment schedules, day 1 was designated as the
day treatment was started.
Results
Tumor lines studied in vitro and/or in vivo are shown in Table 1.
They include both human and rodent cells, the majority from
long-term cultured cell stocks. Their use in vitro and/or in vivo is
indicated by * and # symbols, respectively.
In Vitro (Cell Culture) Studies
Assays and measures of enhancement. In vitro data were reported
in 104 papers with 3 to 32 papers for each drug. Seventy-five percent
of reports employed clonogenic assays alone to determine drug effects
on radiation response, and another 13% employed both clonogenic
and short-term assays (≤5 days, e.g., dye-based or cell counts). In
12%, only short-term assays were used.
Interactions were quantified by a variety of methods, including:
Dose Modification Factor (DMF), Dose Effect Factor or Ratio, or
[Sensitizer or Dose] Enhancement Ratios. These are the ratio of
radiation doses giving an isoeffect level of cell survival with radiation
alone divided by that for radiation plus drug. Other interaction
measures used included isobolograms, ratios of SF2 or SF3 (surviving
cell fraction at 2 or 3 Gy), derived from clonogenic or limiting
dilution assays [4] of survival, Combination Indices [5], ratios of
Mean Inactivation Doses [6], Sensitizer Enhancement Ratios (ratios
of D0s [a measure of the slope in the linear part of cell survival
curves]), or P values of differences in SF with drug alone versus drug
plus radiation. In some cases, the method of analysis was not clear,
not reported, or apparently by eye. One paper employed spheroid
size, morphology, and cell viability in addition to a clonogenic
study [7].
Schedules. Treatment schedules for in vitro studies varied
widely (Supplementary Table 3). A single schedule was evaluated
in 78% of the papers, 2 in 10%, and 3 or more in 12%. One
paper did not report the schedule used. When a drug was given
after irradiation, the duration of drug exposure was generally
reported, but when the drug was given before irradiation, few
papers made clear whether the drug was removed immediately
before or after irradiation or was present throughout the
incubation period.
Drug concentrations and radiation doses. Table 2 shows ranges of
radiation doses and drug concentrations used, and Cmax, maximum
blood concentration at the maximum tolerable dose, or the
recommended dose in patients. Drug concentrations were based on
authors’ claims of clinically achievable concentrations or in vitro
toxicity studies, but generally a rationale was not given.
Drug preparation. Information on preparation and storage of the
drug is important because some drugs are unstable. Twenty-three
percent of the papers reported preparing the drug in DMSO, a known
radioprotectant, without reporting the final DMSO concentration
used or whether it was protective at that concentration.
Table 1. Tumor Lines Studied In Vitro and In Vivo
Drug Tumor Cell Lines (Human Origin, Unless Otherwise Noted)
AZD6244 Colorectal (HT29#, HCT116#*)
NSCLC (Calu-6DC#*, A549#*)
Pancreatic (MiaPaca-2#*)
Prostatic (Du145 wild type# and mutated#)
Bortezomib Breast (MCF-7#)
Cervical (HeLa#, SiHa#*)
Colorectal (WIDR#, LOVO#*, HT29#, KM12L4#)
Esophageal (TE12#)
Glioblastoma (UVW/NAT transfected to express noradrenaline transporter#)
Glioma (TCG3 p53 mutated*, U87 p53 wt*)
Hepatocellular (Huh-7#)
HNSCC (SQ20B with constitutively active EGFR and robust Akt response#, B88*)
Multiple myeloma (MM1#, RPMI 8226#, JJN-3#, ARH-77#)
Neuroblastoma (SK-N-BE[2c]#)
Oral squamous cell carcinoma (B88#, BHY#, HNt#)
Peripheral nerve sheath (NF90.8*)
Prostatic (Du145#, PC-3-Neo (Bcl-2 wild type, deleted PTEN, mutant p53)#
and PC3-Bcl-2 (Bcl-2-overexpressing, deleted PTEN, mutant p53)#
17-DMAG Breast (NCI/Adr-res#, T47D#)
Glioblastoma (U251#)
NSCLC (NCI-H460#, NCI-H460 with scrambled# or KD p53#, A549#)
Pancreatic (PSN1#, MiaPaCa#, AsPC1#)
Prostatic (Du145#*)
Erlotinib Colon (HT29#, HCT-116#)
Glioblastoma (GBM 12*)
HNSCC (SQ20B#*, H226#*, CNE1#, CNE2#*, UT-SCC-5*, SAS*, FaDu*,
UT-SCC-14*, CAL33*)
Lung (A973# origin not reported)
Lung large cell (H460 low EGFR variant#)
Lung squamous (H157#)
NSCLC (A549#, Lu99B#, H23#, H3122#, ABC-1#, HCC44#, Calu-6#,
H460#, H661#, UM-SCC1#, UM-SCC-6*, 38 lines resistant to Erlotinib ±
KRAS mutations#, NCI-H1703, NCI-H1703 with KRAS mutation)
Pancreatic (BxPC-3#*)
Prostate (DU145#*, DU145IRR* subline after 2Gy/d x 5d/w for 6 mo.,
PC3#, ARCaPE epithelial type#, ARCaPM mesenchymal type#,)
Vulvar squamous carcinoma (A431#)
Gefitinib Bladder (HT1376#, J82#*, RT112#, RT4#, T24#, UMUC3#, MGH-U1#
and its radiosensitive mutant S40b#, 253J B-V#)
Breast (MCF-7#, ADR#, MX-1*)
Cholangiocarcinoma (TFK-1# expressing EGFR, HuCCT-1# expressing EGFR)
Colorectal (GEO#*, LoVo#*, LoVo p53 KRAS mutated#)
Ependymoma (IGREP83*)
Esophageal (TE-1#, TE-3#, TE-4#, TE-5#, TE-7#, TE-8#, TE-10#, TE-13#)
Glioblastoma (U251#, U251MG#, U87#, U87MG#)
Glioma (U87MG#, U251#, U-251MG#, SF-767#, BT4C# rat, N0710#
stem-like gliomaspheres, P0710# non-stem-like gliomaspheres, IGRG88*)
HNSCC (CAL27#, CAL33#, CAL60#, CAL166#, Hep-2#, Detroit562#,
HSC2#*, HSC3#*, HSC4#, SCC-1#*, SCC-6#*)
Lung (H-157#, HCC827#)
Melanoma (M14#, MALME-3M#, SK-MEL 2#, SK-MEL 5#, SK-MEL
28#, UACC 257#)
Mesothelioma (JMN*)
NSCLC (NCI-H460#, VRMC-LCD#, A549#* wt EGFR, H1299#,
H596#, Calu-6#, PC9# activating EGFR mutation, SK-LC-16*,
HCC827#* activating EGFR mutation, NCI-H1975# EGFR T790M)
Ovarian (OVCAR-3#)
Pancreatic (MiaPaCa#)
Prostate (PC-3#, DU145#, TRAMP-C1*)
Squamous (SCC-VII# mouse, SCCF1# feline, OC-19#, FaDu#)
Thyroid (ARO# anaplastic, WRO# follicular)
Vulvar squamous (A431 expressing EGFR & HER2/neu#*)
Lapatinib Bladder (RT112 TP53 wt#, RT112 Rad51 KD#, RT112 Ku80 KD#)
Breast (SUM102 EGFR+# and subline constitutively expressing Raf#,
SUM185# Lapatinib-resistant overexpressing HER2, SUM140#, SUM225#*
overexpressing HER2, H16N2-HER2# overexpressing HER2, SUM149*
overexpressing EGFR)
NSCLC (A549)*
Pancreatic (T3M4# wt K-ras, MiaPaCa-2#, Capan-2#, Panc-1#)
Oxaliplatin/
Lipoxal
Breast (CH3/TIF*)
Cervical (HeLa HPV-18+#, SiHa HPV-16+#, CaSki with HPV-16 & -18
genomes#)
Colorectal (HT29#, HCT116 p53 wt#*, S1 from LS-180#,
TABLE 1 (continued)
Drug Tumor Cell Lines (Human Origin, Unless Otherwise Noted)
WiDr p53-mutated#, SW 403 p53 wt#)
Glioblastoma (F98#* rat, U87*)
Hepatocellular (SK-Hep1#)
HNSCC (NT8e#, CAL27#, KB#, Hep2#)
NSCLC (A549#)
Pancreatic (BxPC-3#, Panc-1#)
Sunitinib Breast (4T1 mouse#*, MDA-MB-231#*)
Glioblastoma (GL261* mouse, U87*)
Glioma (Implants from primary mouse gliomas* from mice with conditional
deletions of PTEN, p53, & stop-floxed luciferase using PDGF-IRES-Cre
retrovirus)
Liver (HEP3B#)
Lung (Lewis lung carcinoma* mouse)
Pancreas (MiaPaCa2#, Panc-1#, Panc02*, CAPAN-1*)
Prostate (PC3#*, DU145#, LNCaP# lacks sunitinib target)
Renal (KCI-18/K#*)
Soft tissue sarcoma from genetically engineered mice#*
Thalidomide Esophageal (TE1#)
Fibrosarcoma (FSAII mouse#*)
Glioma (C6/LacZ* rat)
Multiple myeloma (OPM1# mouse, OPM2# mouse)
Squamous cell (SCC-VII# mouse)
Vorinostat Breast (MCF7#, MDA-MB-231-BR#*, T47D#, 4T1#* mouse)
Colorectal (HCT116#*, HT29#, KM20L2#, SW620#*)
HNSCC (SCC-25#)
Liver (HEP3B#)
Medulloblastoma (DAOY#)
Melanoma (A375#, MeWo#)
Multiple myeloma (U266B1#, RPMI8226#, MM1.s#, KMS-11#)
Neuroblastoma (NB1691luc#*, Kelly#, SY5Y#, MYCN inducible
Tet21 with MYCN overexpressed# or repressed#)
NSCLC (A549#)
Osteosarcoma (KHOS-24OS#, SAOS2#)
Ovarian (NCI/ADR-RES#)
Pancreatic (MiaPaCa2#, AsPC-1#, Colo357FG#)
Rhabdomyosarcoma (A-204#*, RD#)
Cell line not specified
#: in vitro studies; *: in vivo studies.
Table 1. (continued)
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replicates. Of the 77 in vitro papers that tested cell survival using
a clonogenic assay at more than one radiation dose level, only 32%
mentioned adjusting plate size and/or number of cells plated to
achieve statistically comparable numbers of colonies counted in
controls and irradiated groups at all radiation doses [8]. None
indicated selecting an incubation time on the plateau of the increase
in colony number over time or adjusting the termination date of
experiments to achieve comparable colony sizes to account for
drug-induced growth delay [8]. Sixty-eight percent of papers reported
repeating the experiments; 32% did not provide information on the
number of repeats; 42% did not report having replicate plates.
Irradiation. Radiation sources used for both in vitro and in vivo
studies are shown in Supplementary Table 4. X-ray, 137Cs, and 60Co
sources were the most commonly used. Linear accelerators and
neutrons were less frequently used. Fourteen percent of reports were
unclear or did not report the radiation source.
Problems. Eighty-three percent of the in vitro studies had one or
more problems that would make interpretation or replication of the
study difficult, or could lead to erroneous conclusions (Table 3). The
most common problem was incomplete or unclear description of
methods. The next most common error was a prolonged delay
between plating of cells and irradiation, which raises questions as to
the multiplicity of cells (single or clusters of two or more cells) at the
time of radiation exposure; some papers did not report this
information. Only one paper with in vitro studies reported blinded
Table 2. Ranges of Radiation Doses and Drug Concentrations Tested In Vitro and Drug Concentrations Achievable in Patients
Drug Range of Radiation Doses, Gy Range of Drug Concentrations Cmax at MTD* or Recommended Dose**
AZD6244 2-10 100-250 nM
(46–114 ng/ml)
486-718 ng/ml**
(1060-1600 nM) [58]
Bortezomib 1-16 0.68 nM-50 μM
(0.4-19,000 ng/ml)
20 (s.c.)-160 (i.v.) ng/ml**
(50-420 nM) [59]
17-DMAG 2-8 10-100 nM
(6.2-62,000 ng/ml)
500 ng/ml*
(800 nM) [60]
Erlotinib 0.5-10 0.1-10 μM
(0.04-4 μg/ml)
150mM (probable error); dose not given
1340-1450 ng/ml**
(3.4-3.7 μM) [61]
Gefitinib 0.5-10 0.005-200 μM
(2.2-900 ng/ml)
159 ng/ml @250 mg dose (oral)**
(0.36 μM) [62,63]
Lapatinib 1-10 0.6-2.5 μM
(0.35-1.45 μg/ml)
2.43 μg/ml @ 1250 mg dose**
(4.2 μM)) [64,65]
Oxaliplatin 0.5-15 0.5-1000 μM
(200–400,000 ng/ml)
3.5-3.8 ng/ml**
(0.009-0.010 μM) [66]
Lipoxal 2.2-2.3 1.25-20 μM
(0.5-8 μg/ml)
9.2-12 μg/ml
(23-30 μM) [67]
Sunitinib 2-10 0.01-1 μM
(40ng-4 μg/ml)
73 ng/ml*
(0.2 μM) [68]
Thalidomide 0.4-12 2-150 μM
(0.5-39 μg/ml)
1.81-2.82 μg/ml @ 400 mg dose**
(7-11 μM) [69–71]
Vorinostat 0.5-40 0.2-2.5 μM
(528 – 1320 ng/ml)
1.3 ng/ml*
(0.005 μM) [72,73]
MTD, maximum tolerable dose. The single asterix (*) indicates dose at the MTD the double asterix (**) indicates recommended dose for use in patients.
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about) necessary radiation parameters: source (14%), energy (19%),
dose rate (38%), setup (76%), and equipment calibration (92%).
In Vivo (Animal) Studies
Assays and schedules of treatment. In vivo studies were reported in
51 papers, with 1 to 11 papers for each drug. Most (90%) employed a
growth delay assay in mice with transplanted tumors. Tumors were
treated and their growth followed either for the number of days to
reach a given multiple of tumor volume at the start of treatment or to
the relative volume at a given number of days after treatment. Tumors
implanted orthotopically in the brain or kidney were measured using
magnetic resonance imaging, bioluminescent imaging, or weight after
sacrifice. Other assays used were animal survival duration (mean or
median survival time, Kaplan-Meier plots [20%]), tumor-free survival
(2%), TCD50 (radiation dose for local tumor control in 50% of
subjects, 2%), size of lytic bone lesions (2%), and in vivo treatment
followed by an in vitro assay (2%). In some papers, multiple assaysTable 3. In Vitro Papers with Problems, of 104 Papers
Number of
Papers
Problem
42 Incomplete or unclear methods
45 Possible multiplicity (clumps) of cells at time of irradiation: N8 h between plating and
irradiation or time between plating and irradiation not reported
24 DMSO (a radioprotectant) used as vehicle, concentration not given
24 Statistical problems (including error bars not identified, too many significant figures)
16 Conclusions not supported by data (e.g., claim of radiosensitization despite large
overlap of data, “therapeutic gain” without studies in normal tissue cells
16 Textual discrepancies or proofing errors
17 Data plotted improperly: radiation dose not on linear scale, surviving fraction not on
log scale, radiation dose in μM units, ratio to drug dose or IC50
14 Data not shown, or only “typical” or “representative” data shown
12 Short-term assay only (dye-based or cell counts), with radiation
4 Vehicle not reported
3 Incorrect or missing reference in methods
3 Controls missing or not shown
1 Plating efficiency determined in separate experiment
1 Data not discussedwere used. The schedules used in in vivo studies are shown in
Supplementary Table 5.
Group sizes and repeats. Seventy-eight percent of the papers had
at least five 5 subjects per group in all groups. Eighteen percent had
one or more groups with less than five 5 subjects, and 4% did not
report group size. Only 12% of papers with in vivo studies reported
that they repeated their experiments; the rest presumably ran their
studies only once.
Problems. Problems identified in the in vivo studies are shown in
Table 4. The exact timing of drug and radiation was rarely reported
for the days when both were given together in multifraction
treatment. Only two papers with in vivo studies reported data
collection by an observer blinded to the treatments received.
Randomization of animals to treatment groups was reported in
76% of the papers, but none reported the method of randomization.
Only one paper reported using power calculations to determine
appropriate sample sizes, and none of the others justified their choice
of group sizes. As with in vitro studies, necessary radiation parameters
were not reported or unclear: source (20%), energy (37%), dose rate
(43%), setup (45%), and equipment calibration (88%).Enhancement of Radiation Response
After compiling the above data, we asked whether the preclinical
data for any of these drugs would show sufficient promise to warrant
clinical trials. Among the 125 papers reviewed, 282 drug-tumor line
combinations were studied with radiation, with a total of 517
experiments. We analyzed the results in two steps (Supplementary
Tables 6 and 7).
The in vitro studies that could be used to evaluate the
drug-radiation combinations (designated “useable”) were those
conducted at clinically achievable drug concentrations, reported
drug and radiation doses and schedules, used clonogenic assays and
reported a DMF, or had survival curves from which DMFs could be
estimated. “Positive” studies had a DMF N1.1. Experiments using
other measures of effectiveness, including subjective assessments,
were then added. All in vitro studies with oxaliplatin and vorinostat
Table 4. In Vivo Papers with Problems, of 51 Papers
Numbe r o f
Papers
Problem
25 Exact timing between drug and irradiation not given
17 Tumor size at start of treatment: Tumors ≤5 mm diameter, unequal size among
groups, or not reported
12 Unexplained discrepancies in text, figures, or figure legends
13 Statistical problems: error bars not identified or not shown, mixed use of SE and
SD, mean and median, large differences in tumor size at start of treatment, growth
delay data censored to time and not to size
7 Drug dissolved in DMSO, a radioprotectant, with final concentration not given,
or vehicle not identified
5 Methods unclear
6 Conclusions not supported by data: claim for differing growth rates with growth
curves congruent or parallel after lag, growth delay curves continued after loss of
animals from group, therapeutic benefit claimed with no normal tissue studies
4 Data not shown, or only "typical" or "representative" data shown
3 Radiation or drug dose not reported, or duration of treatment not given
3 Interaction terms undefined (synergism, etc.)
3 Group size small (N ≤ 5)
2 Control groups not done or not shown
2 DMF/Dose Effect Factor calculated with single radiation dose level
1 Whole-body irradiation for localized tumor
1 Curves from control and experimental groups plotted separately
3 Inconsistent/incomplete reporting of data
1 Data pooled from several schedules
1 Unusual responses not discussed or explained (disappearance of 6- to 8-mm–
diameter tumors after 5 Gy)
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and in vivo results were mixed. For most of the other drugs, results
varied with tumor line, drug and radiation dose, and schedule.
The in vivo studies that could be used for similar intercomparisons
(designated “useable”) were those that reported drug and radiation
doses and schedules and reported data from growth delay, tumor
volume, or survival studies, or those from which these end points
could be estimated from the published figures. Only one paper
reported DMFs, using TCD50 assays. We did not attempt to
compare these drug doses to those in patients; tolerance levels and
pharmacodynamics can differ significantly between species. In only
five cases were replicate studies reported, with the same tumor line,
drug and radiation doses, and schedules. In all cases, the replicates
were from the same laboratory but not always with identical results.
Thus, despite the many experiments performed, there were no
assessments by different laboratories of any unique combination of
variables including drug, tumor line, drug and radiation dose, and
schedule.
We then considered the effects of drug doses and schedules
(Supplementary Table 7) and attempted to determine if there was a
consistent message about the interactions of these drugs with
radiation. It was helpful when a series of tests was done in which
only a single parameter was varied: tumor line, drug concentration or
dose, radiation dose or dose range, or treatment schedule. Higher
drug doses or durations, higher radiation doses, or fractionation of
radiation treatment were not always more effective. Different
schedules did not always result in different responses. Of the 10
drugs surveyed, only 6 had 1 or more tumor lines with “useable” data
both in vitro and in vivo.
Sunitinib failed to enhance radiation response either in vitro or in
vivo. AZD6244, bortezomib, 17-DMAG, and gefitinib showed
positive results in vitro, but had few studies and/or mixed results in
vivo. Erlotinib showed mixed results in vitro but was mostly
ineffective in vivo. Lapatinib, LipoxalTM (Regulon, Inc, Athens,Greece), and thalidomide had mixed results but insufficient in vivo
data to determine which variables might account for the differences.
Oxaliplatin showed mixed results in vivo; one study indicated that
higher drug doses were effective and lower doses ineffective, but other
studies were positive at those lower doses. Vorinostat showed no clear
patterns or consistent results in vivo even when nearly identical
schedules and drug doses were used; radiation doses and fractionation
varied widely, so comparisons among studies were not possible.
Discussion
In Vitro Studies
Assays. In patients, it is the survival of the few cancer cells, not
the death of the many, that leads to recurrences and new metastases
months to years after therapy. Clonogenic assays are therefore
considered the gold standard for assessing cell survival in vitro
following radiation exposure [9] because they measure cell survival
and are independent of modes of cell death (mitotic catastrophe,
apoptosis, senescence, necrosis, or autophagy [10]) and the time
intervals over which they occur. Lethally irradiated cells usually have
prolonged cell cycles and die after one or several cell divisions [11].
Clonogenic assays allow time for elimination of cells not capable of
sustained proliferation. The incubation period used should be on the
plateau of the plot of colony number versus time, which can be
different for controls and drug/radiation groups. Cell lines that do not
attach well or that tend to migrate can be used for colony-forming
assays if measures are taken to immobilize the cells during colony
formation, such as growth in agar. Alternatively, survival can be
determined through Poisson statistical analysis of limiting dilution
clonogenicity, as adapted from Lefkovits [4].
Short-term assays such as cell counts or the MTT or other
dye-based assays tend to overestimate cell survival because they count
as survivors metabolically active cells that will ultimately die. Whereas
short-term dye-based assays are commonly used to assess drug toxicity
or cell growth rates, they are unreliable for determining radiation cell
survival. Although short-term clonogenic assays have been proposed
for high-throughput screening of drugs and radiation [7,12–14], they
should not be used with slowly proliferating cell lines, for lines that do
not form discrete colonies [14], or for drugs that delay or slow cell
proliferation. They must be validated for both cell lines and drugs,
and leads verified with more detailed studies using standard
clonogenic assays.
Drugs that slow or halt cell division or kill cells affect both plating
efficiency and optimal incubation time for colony formation.
Therefore, colonies from drug-treated cultures should be counted
when the colony size of the unirradiated cultures treated with drug is
equivalent to that of untreated controls. This may require incubating
drug-treated cultures several days longer than controls. None of the
papers reported adjusting incubation time for drug effects on colony
growth rate. This is especially problematic when drug exposure is
continued during colony development after irradiation. Drug-in-
duced growth inhibition can also delay tumor growth and must be
reported and considered in interpretation of the data.
Survival curves from drug-treated groups that are normalized for
toxicity of the drug in the absence of radiation can be more easily
compared with the radiation-only curve, but plating efficiencies of all
control and test groups should be reported as an indication of drug
toxicity, which contributes to the total response. Colonies with ≥50
cells represent N5 cell divisions, if all dividing cells survive.
Table 5. Checklist
To Be Reported For All Studies In Vitro Studies In Vivo Studies
Drug(s) used • Names (if more than one)
• References to structure and characteristics
• Preparation, storage, vehicle, dilution,
final concentration
Radiation • Details on radiation source, dosimetry,
dose rate, beam characteristics and
filtration for x-ray/linac sources and radiation
setup including buildup or backscatter characteristics
• Statement of irradiator constancy
measurements and output
traceability to National Standards.
• References to written irradiation standards
and/or protocols used. Examples of relevant
radiation factors and their concise
description for publication are given
in the appendix of [41,42]
http://dx.doi.org/10.6028/jres.118.021.
• Setup used for the study • Setup, shielding and shielding efficacy
• Use of restraint and/or anesthesia.
Cell/tumor
line(s) and
culture conditions
• Name, tumor type, tissue and species of
origin and relevant molecular profile, if known
• Test results for validation of identity and
pathogen status.
• Proliferation status and multiplicity at the start of treatment
• Medium and serum concentrations, use of other additives
such as antibiotics, incubator oxygen and CO2 concentrations
and any non-standard incubation conditions, including hypoxia,
variations in temperatures used, plating in suspension (e.g. methylcellulose,
agar, Matrigel, etc.) or on other matrix or substrate
• Tumor size at start of treatment, metastatic
potential, tumor doubling time, and whether
treatment was started when tumors reached a
given size or at a given time after implantation.
• Tumors should be sufficiently large at the
start of treatment to have biological properties
of established tumors and to facilitate accurate
measurement.
• Tumor transplantation procedure, site, method
and frequency of measurement.
Assay(s) used • Assay used • Clonogenic assay: minimum cells/colony, plate size,
adjustments in number of cells plated and/or plate size,
duration of incubation time to achieve equal colony
sizes and counts among drug-treated, irradiated, and
combined-treatment groups
• Justification for duration of posttreatment
incubation time (i.e., on plateau of curve of colony
counts vs incubation time).
• Growth delay: measurements made and cutoff
criteria: tumor size, number of days after
treatment, euthanasia criteria
• Dye-based short-term assays (e.g., MTT and similar
assays) or those focused on a single mode of death
(e.g., apoptosis) are not appropriate for use with
radiation without verification by comparison with
standard clonogenic assays in the cell lines used for the study.
• Promising results from pilot studies at a single
radiation dose level or short-term high throughput
clonogenic assays should be followed up with standard
clonogenic assays using ≥3 radiation dose levels plus
unirradiated controls.
• Survival time: euthanasia criteria
• Animal husbandry practices (e.g., conventional
or defined flora colony)
• Possible cage effects, if animals in a given
treatment group were caged together or
distributed among different cages
• For other in vitro assays (e.g. spheroids): criteria
and end points used
• TCD50 assays:
maximum follow-up time, euthanasia criteria
Controls • Appropriate concurrent drug-only,
radiation-only, vehicle-only controls
Schedule(s) • Drug administration and irradiation
schedules and their rationale.
• Drug duration and removal • Route of drug administration and exact timing,
especially when treatments are given over
several days.
Plotting of data • Clonogenic assay with multiple radiation dose levels:
Log of surviving fraction vs linear radiation dose
Statistics and software • Statistics and software used
• Error bars used (conf. interval, SD, or SE,
and appropriate use of the latter)
• Number of independent experiments performed
• Inclusion of full data set in supplement if
"representative data" are shown
• Detailed methodology for measuring effects
(e.g. enhancement)
• Consult with a statistician both during
planning of experiments and analysis of
data to determine appropriate statistical tests
and group sizes
• Number of replicate plates used for each group
• Curve-fitting model and DMF when full survival
curves are obtained, not just P value.
• Number of animals/group
• Power calculations to justify group size
• Number of independent experiments performed
• Method for handling of censored data.
• Initial variance within groups
Blinding • Perform blinded counting of colonies or other end point
measurements
• Method of randomization to treatment groups
and whether experiment was carried out
double-blinded
Interpretation of data • Verify appropriateness of interpretation of data
Final check • Proofread to ensure clarity, consistency and
accuracy of methods in text, figures, and figure legends.
• Verify references to previously published
methods and report any differences.
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for study is important, although the best model for a given assessment
is still a matter of debate. Our suggestion is that for targeted agents,
lines having the target should be used and compared with effects in
isogenic lines and others lacking the target to verify that the agent is
affecting radiation response through the predicted mechanism [15].
Voskoglou-Nomikos et al. [16] examined the predictive value of
in vitro, mouse allograft, and human xenograft models for Phase II
clinical response to 26 cytotoxic cancer drugs in breast, non–small cell
lung, ovarian, and colon cancers. The mouse allograft model was not
predictive, but results with in vitro and xenograft models varied with
tumor type and model. These studies did not, however, involve
radiation. The use of a single cell line or tumor model is clearly
insufficient as a guide for eventual clinical testing. Extensively
cultured cell lines may result in tumors that no longer reflect the
characteristics of the tumors from which they originated [17]. A panel
of low-passage, genetically annotated cells might provide more
accurate assessment of clinical potential but should be validated. The
identity of all cell lines should be validated. Testing for pathogens that
can impact radiosensitivity or tumor growth (e.g., mycoplasmas and
murine viruses) should be carried out before the studies and reported.
Survival curve interpretation. Reduction in the shoulder of the
radiation survival curve may result from cell cycle-selective
sensitization [18] by a drug or from a reduction in the capacity to
repair radiation damage [19]. Studies carried out at a single radiation
dose level are insufficient to reveal whether the drug shows merely
additive toxicity or affects the slope or shoulder of the radiation cell
survival curve, with implications for multifraction irradiation.
Therefore, full radiation survival curves should be obtained to
determine whether the drug changes the slope of the survival curve
(radiosensitization) or reduces the shoulder. In the latter case,
multifraction studies would be informative. Only two papers reported
in vitro data using more than one fraction of radiation, but both used
only a single radiation dose level, and one used only a short-term
dye-based assay. None reported studies with synchronous cells.
Microenvironmental effects. Microenvironmental influences such
as hypoxia and cell-to-cell and cell-matrix interactions can have a major
impact on survival [20–23]. Cell culture conditions do not usually
mimic the heterogeneity in solid tumors growing in a patient or
orthotopically implanted in immunosuppressed animals, where oxygen,
nutrient, and drug concentrations vary in space and time [24–27].
Vascular and supportive tissues are present in vivo, cell densities are
generally much higher than those in vitro, and tumor size can affect
response. Most in vitro studies employed exponentially growing cultures
or those treated soon after plating, with cells in lag phase. Slowly or
nonproliferating stem cells may predominate in patients andmay govern
response to therapy. If they are recruited to active proliferation during
the course of fractionated treatments, models that more closely mimic
their biology and radiobiology might be more predictive of clinical
responses [28]. Use of confluent cultures replated for clonogenic survival
immediately after treatment may partly overcome this deficiency.
Hypoxic conditions and 3D cultures that allow cellular interactions with
matrix or stromal elements, etc., can reveal how these factors influence
tumor response in vivo. Cells that do not form colonies easily or have low
plating efficiencies may be assessed in 3D cultures, conditioned
medium, or sterilized feeder layers from appropriate cells [29]. These
methodologies are not currently used for routine screening.
Measurement of enhancement and terminology of interactions. As
described by Steel and Peckham [30], there are four ways in whichcombinations of drug and radiation can improve therapeutic efficacy:
spatial cooperation, where both modalities interact in a defined and
limited anatomical site such as the tumor; nonoverlapping toxicity;
protection of normal tissue; and enhanced tumor response. Here we
focus on the last of these possible interactions. Studies at a single
radiation dose level using the Combination Index of Chou and
Talalay [5] or ratios of SF2Gy are difficult to compare. Small
uncertainties in these estimates will be magnified if extrapolated to 30
fractions. Nonlinear regression analysis should be used to compare
radiation survival curves [31]. To determine DMFs at the standard
10% SF, the highest radiation doses must reduce SFs to ≤10% in all
groups, with normalization of drug data to 100% SF. However, it is
important to keep in mind that DMFs depend on the shapes of the
normalized survival curves and the surviving fraction at which they
were measured. In addition, the cumulative effects of any toxicity to,
and radiosensitization of normal tissues and cells should be less than
that observed for tumors. Enhancement of treatment effects assessed
by a standard method would allow straightforward comparisons
among drugs, laboratories, and tumor lines. Possibilities for spatial
cooperation and nonoverlapping toxicities in sparing normal tissues
should also be considered in evaluating the activity of radiation-drug
combinations. In considering the ultimate clinical application of a
combination, the volume of normal tissue and the extent of its
damage in relation to total organ volume may allow for use of a
therapy that produces major damage but spares an adequate
functional volume.
Statistics. Statistical concerns in published papers have been
presented [2,32]. Similar problems were observed in the papers we
reviewed, including mis- or nonidentification of error bars, masking
of variability by presentation of "representative" data, inappropriate
calculation of P values and error bars, and use of inappropriate
statistical tests. These will not be enumerated here. The most
commonly reported statistic was the P value, which measures the
probability of obtaining the given test value when control and test
groups are in fact not different (the null hypothesis). However, as
stated by Gertrude Stein, "A difference, to be a difference, must make
a difference." Because an important goal in preclinical studies of drugs
and radiation is to identify and prioritize combinations for clinical
trials, a more useful and robust statistic is a measure of the magnitude
of the enhancement, such as a DMF with a 95% confidence interval.
This requires testing at multiple radiation dose levels. The minimum
DMF that should be required before proceeding with clinical
radiotherapy trials has not been settled, but the 95% confidence
interval for the DMF should at a minimum exclude 1. In addition,
any drug giving a DMF of less than 1.2 is not likely to be successful in
the clinic.
Drug concentrations. Drugs should be tested at clinically relevant
exposure times and concentrations: at or below the Cmax from Phase
I trial data, if known. Lacking this information, a range of drug
concentrations should be tested and combined with tests of the effects
on target proteins and/or pathways. A reasonable approximation of
the duration of drug exposure in patients should be made. When
in vivo tolerability information is obtained, a decision can then be
made on feasibility and design of animal studies.
In Vivo Studies
As with in vitro studies, cell lines used for in vivo evaluation of
drug-radiation interactions should be representative of human tumors
and have the relevant targets of the drug being tested. Subcutaneous
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more like tumors in patients in temperature, metabolism, stromal
composition, vascularization, and chemosensitivity [33,34] but are
more difficult to measure, usually requiring either advanced imaging
technology or sacrifice of the animal.
Tumor lines that have been passaged exhibit genetic and
physiologic drift from their primary tumors and may not respond
in the same manner as the primary tumor in situ. Camphausen et al.
[35] have found differences in gene expression in untreated and
irradiated cells from brain tumors grown in vitro or as subcutaneous
or orthotopic xenografts, but the effects of these differences on
radiation response have not been tested in clonogenic, growth delay,
or TCD50 assays. Recent adoption of genetically engineered mouse
models and patient-derived xenografts may mitigate the drawbacks of
established cell line xenografts but are costly. Both genetically
engineered mouse models and patient-derived xenograft models
appear to have good predictive value regarding tumor responses to
therapy [36] but need further verification.
Assays. The growth delay assay is the most frequently used assay
for in vivo studies, but it can overestimate the effectiveness of drugs
that temporarily inhibit growth but do not kill cells [37,38]. The time
for tumor regrowth, particularly for doses greater than 12 to 15 Gy,
can be influenced by the tumor bed effect (slower growth of a tumor
from vascular/stromal damage in the irradiated site) [39]. This effect
can be minimized if the size of the tumor at the conclusion of the
assay is ≤2× treatment volume. The TCD50 assay for local tumor
control is a measure of complete eradication of tumor cells but is more
difficult, takes longer to carry out, requires more animals, and is more
costly.
The value of single-fraction radiation studies is controversial. As
indicated above, they can be useful for determining the effect of a
drug on the survival curve of proliferating cells and the effects of
scheduling of drug and irradiation on interactions in in vitro studies.
Two-fraction experiments can then indicate whether the interaction is
enhanced or reduced by fractionation. Similar comparisons with
in vivo data can also indicate whether enhancement decreases with
fractionation. Multifraction experiments can be prohibitively costly in
time and animal health, especially if repeated anesthesia is required,
but are more “clinically mimetic” than a single dose. Whether
30-fraction experiments that model the typical clinical fractionation
regimens are necessary or whether fewer fractions would suffice has
not been established. Drug-radiation interactions may be influenced
more by the radiation dose per fraction than the number of fractions.
Timing of start of treatment. Tumors were treated starting either
at a fixed interval after implantation, when tumor sizes vary
considerably, or on the day each tumor reached a given size. Some
of the papers reviewed did not report this information. When growth
curves were normalized, group differences in size at the start of
treatment could not be discerned, but if tumor characteristics
changed with size, this could have affected treatment response and
conclusions. Although an ideal starting tumor size cannot be
prescribed, the tumors should be fully established and their size
distribution at the start of treatment reported. Tumor growth rates in
patients are generally slower than spontaneous or transplanted human
or rodent tumors in rodents. Serial transplantation selects the
fastest-growing subpopulations [40]. In some studies, treatment was
initiated when tumors were ≤25 to 50 mm3. It was not clear how or
how accurately such small tumors were measured, or whether they had
the response characteristics that might be relevant to tumors in patients.Statistics. A minimum of five animals per group has been
recommended for growth delay experiments, but when tumor growth
rates in untreated animals vary considerably, more are needed to
distinguish treatment effects from underlying variability in tumor
growth rates. Larger group sizes are also needed when tumor size is
measured less precisely, as with fluorescence imaging with orthoto-
pically implanted tumors. More precise measurements (magnetic
resonance imaging, computed tomography, ultrasound) are prefera-
ble, but the additional radiation dose to the tumor from computed
tomography must be considered and reported.
Physics and Dosimetry
With deficiencies in reporting dosimetry and irradiation setup, it
was not possible to know whether researchers had accounted for such
factors as dose from backscatter, uniformity of dose across the
radiation field or through the depth of the tumor, absorption by
overlying culture medium, culture vessel or tissues, and whether
dosimetry had been carried out under the same conditions as the
experimental setup or was traceable to equipment calibrated by the
National Institute of Standards and Technology. Lack of this
information makes it impossible to replicate the studies and to
compare results within and among laboratories [41,42].
Rationale
The rationale for the design of the studies was rarely given in the
papers we reviewed, and few reported systematic studies to determine
optimal combinations of drug and radiation doses and schedules that,
with information on pharmacokinetics and pharmacodynamics in
rodents and humans, could be helpful for translating preclinical data
into clinical trials. Smith and Houghton have pointed out the
importance of clinically relevant drug concentrations for studies
in vitro[43]. If this is not known at the time of study, a range of drug
concentrations/doses should be studied so that when human
pharmacokinetic studies have been performed, the effectiveness of
the relevant concentration can be inferred from data already available.
A variety of schedules should be studied to determine whether
interactions vary with schedule. For a molecularly targeted drug, it is
important to determine if the target is affected by that drug
concentration or dose. The lowest drug concentration that affects the
target should be used for radiation studies. If radiosensitization occurs
only at higher concentrations, “off-target” effects may be occurring.
Carefully designed in vivo studies should be more informative about a
drug's likely performance in more complex environments in patients.
Future preclinical and clinical studies will be based on tumor biology
rather than histological subtype, using biomarkers to assess
response [44].The Next Steps
Methodologies for assessing tumor cell and tumor radioresponse
are continually evolving, and new assays and methods may enhance
the speed, sensitivity, selectivity, and predictive power of preclinical
studies. In addition to the high-throughput clonogenic assays
mentioned above, other innovations include methods and reagents
that allow for control and modifications to culture substrata and
oxygenation [22,26,45–47]. Genetically engineered mouse models
are being developed that mimic conditions in spontaneous tumors
[48]. Patient-derived xenografts also offer the potential for conduct-
ing “co-clinical trials” with tumors that retain characteristics of the
parent tumor for several passages [49]. Although adoption of these
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testing involving radiation, the results must be validated with patient
clinical trial data.
In the clinic, radiotherapy is rarely used as the sole treatment
modality. New drugs are tested in clinical trials as additions to
“standard of care” regimens comprised of surgery and other drugs.
Although we examined only data for single agents tested with
radiation, several of the papers in this survey reported studies of
combinations of two or more drugs with radiation, and relevant
combinations of agents should be studied before initiating clinical
trials [50].
It is important for researchers to understand both the limitations of
their models and the complexity of the disease and its treatment in
patients. Intratumor heterogeneity of the target can reduce the
effectiveness of molecularly targeted agents in patients. Many
differences between cell culture, rodent models, and human patients
have been pointed out [16] and must be considered when designing,
conducting, and interpreting results of preclinical studies and, in
particular, in recommending and designing subsequent clinical trials.
Checklist of Information Required for Publications
on Drug-Radiation Effectiveness
A proposed checklist for researchers and reviewers of preclinical
studies evaluating the effectiveness of drugs with ionizing radiation is
given in Table 5.
Conclusions
Several of the drugs surveyed may warrant further study to define
their optimal use: bortezomib, 17-DMAG, gefitinib, lapatinib,
Lipoxal, and vorinostat. AZD6244, erlotinib, oxaliplatin, and
thalidomide do not appear promising, although they have not been
extensively studied. Sunitinib, despite few in vitro studies that could
be evaluated, showed positive results in only 1 of 16 in vivo studies
and is not recommended for clinical radiotherapy trials.
Many of the problems identified in these preclinical studies are not
unique to the field of drug-radiation studies. Multiple recommen-
dations have been made to improve the quality of preclinical scientific
research and publications (e.g. [2,51–54]). Guidance specific to the
study of drug-radiation combinations has been published (e.g. [55–
57]) but has not identified the problems reported here and has not
focused on the need to be able to compare results from multiple drugs
and multiple laboratories. The number and diversity of variables
among the studies surveyed here, including tumor sizes, types and
transplant sites, drug and radiation doses, schedules of drug and
radiation administration, assays and end points, and criteria for
interpretation of interactions, made it difficult to collate this
information into robust guidance for clinical trials. In preclinical
research, there is a need to balance the freedom to explore many
tumor lines, drug doses, radiation doses, mechanisms, and schedules
with the larger mission of improving tumor response in cancer
patients treated with radiotherapy. This requires sufficient, relevant,
robust, accurately reported data. Effects should be quantified with
common measures so that data from different laboratories can be
compared, and to provide a sound basis for decisions and designs for
clinical trials [3]. It is important for researchers to fully justify the
rationale for experimental design. Although no preclinical model or
study will perfectly predict clinical response, it should provide
clinically informative data. When clinical trials are completed, it will
be important to compare the results with the preclinical data so that
the models used and predictive value of preclinical studies can beimproved. Investigators, grant and journal reviewers, and editors have
a critical role in ensuring that studies are responsibly conducted and
reported, and reviewed by persons with a relevant background in
radiation biology.
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